Effects of Atorvastatin on Myonecrosis
NCT00344019 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. As of 21 Nov 2026, it was terminated. It studies Atorvastatin and Placebo in Coronary Disease. The registry lists an enrollment of 97 participants at 1 site in 1 country. The registry lists a start date of 31 May 2006 and a primary completion date of 31 Oct 2008.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00344019 |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Beth Israel Deaconess Medical Center |
| Enrollment | 97 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Coronary Disease |
| Drugs | Atorvastatin and Placebo |
| Start | 31 May 2006 |
| Primary completion | 31 Oct 2008 |
| Study completion | 31 Jan 2009 |
| Last update posted | 2 Jan 2018 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joseph Carrozza, Jr, MD
Beth Israel Deaconess Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beth Israel Deaconess Medical Center
Boston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00344019
Each answer restates registry values shown on this page.
What is NCT00344019?
NCT00344019 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. It studies Atorvastatin and Placebo in Coronary Disease.
Who leads NCT00344019?
The registry names Joseph Carrozza, Jr, MD (principal investigator, Beth Israel Deaconess Medical Center) as the overall official.
Where does NCT00344019 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00344019 study?
The registered drug and biological interventions are Atorvastatin and Placebo.
When did NCT00344019 end?
The registry lists a primary completion date of 31 Oct 2008 and a study completion date of 31 Jan 2009. The sponsor last updated the record on 2 Jan 2018.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.